Q32 Bio Inc.
QTTB
$1.61
-$0.075-4.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -14.66M | -12.80M | -9.60M | -6.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -14.66M | -12.80M | -9.60M | -6.65M |
| Cost of Revenue | 48.14M | 45.94M | 39.05M | 33.66M | 31.73M |
| Gross Profit | -48.14M | -60.60M | -51.86M | -43.26M | -38.38M |
| SG&A Expenses | 17.96M | 16.79M | 14.51M | 12.47M | 9.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.10M | 62.72M | 53.57M | 46.13M | 41.60M |
| Operating Income | -66.10M | -77.39M | -66.37M | -55.73M | -48.26M |
| Income Before Tax | -47.71M | -58.73M | -55.10M | -45.38M | -53.43M |
| Income Tax Expenses | 21.00K | 1.88M | 1.94M | 494.00K | 318.00K |
| Earnings from Continuing Operations | -47.73 | -60.61 | -57.05 | -45.88 | -53.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.73M | -60.61M | -57.05M | -45.88M | -53.74M |
| EBIT | -66.10M | -77.39M | -66.37M | -55.73M | -48.26M |
| EBITDA | -65.62M | -76.89M | -65.88M | -55.23M | -47.76M |
| EPS Basic | -3.01 | -78.22 | -117.29 | -132.56 | -153.43 |
| Normalized Basic EPS | -2.56 | -37.30 | -61.63 | -71.25 | -84.41 |
| EPS Diluted | -10.37 | -85.59 | -124.65 | -139.92 | -153.43 |
| Normalized Diluted EPS | -2.99 | -37.73 | -62.06 | -71.68 | -84.41 |
| Average Basic Shares Outstanding | 37.22M | 25.39M | 13.66M | 2.04M | 1.39M |
| Average Diluted Shares Outstanding | 38.56M | 26.73M | 15.00M | 3.38M | 1.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |